Ling Geoffrey M.D.
Known title: DirectorCIK: 0001800097
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Gyre Therapeutics Schedules Investor Meetings for September. Gyre Therapeutics has announced participation in upcoming investor conferences scheduled for September. The company will engage with institutional investors and analysts through these scheduled meetings. Shares are currently trading near established support at $6.32, within a 52-week range of $5.44 to $9.42. Three analysts currently maintain an average price target of $18.67.
Transaction History
| CELU | ▲ Buy | Grant | 19,231 | $0 | 1/12/2026 | View on chart |
| CELU | ▲ Buy | Grant | 125,000 | $0 | 12/29/2025 | View on chart |
| CELU | ▲ Buy | Grant | 67,416 | $0 | 12/19/2025 | View on chart |
| CELU | ▲ Buy | Grant | 44,379 | $0 | 11/19/2025 | View on chart |
| CELU | ▲ Buy | Grant | 67,416 | $0 | 12/19/2024 | View on chart |
| GYRE | ▲ Buy | Grant | 12,855 | $0 | 1/7/2022 | View on chart |
| GYRE | ▲ Buy | Grant | 2,858 | $0 | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Celularity Q1 2027 EPS Up, Announces Partner & Board Member
Celularity posted a first‑quarter 2027 earnings per share of $0.02, up from a loss of $0.84 a year earlier, while sales fell to $3.85 million from $11.43 million. The company will open the Fontaine Vitale facility with its strategic partner and added Naveen Jain to its board. It also closed a $10 million private placement of senior secured convertible notes and warrants, part of a $28 million recapitalization plan.
Celularity Q1 2027 EPS Up, Announces Partner & Board Member. Celularity posted a first‑quarter 2027 earnings per share of $0.02, up from a loss of $0.84 a year earlier, while sales fell to $3.85 million from $11.43 million. The company will open the Fontaine Vitale facility with its strategic partner and added Naveen Jain to its board. It also closed a $10 million private placement of senior secured convertible notes and warrants, part of a $28 million recapitalization plan.